Covant acting CEO Matt Maisak (L) and CSO Iván Cornella

With Boehringer In­gel­heim’s help, Roivant churns out an­oth­er Vant to go up against En­deav­or, Im­pact founders

Roivant Sci­ences has added an­oth­er branch to its fam­i­ly tree, un­veil­ing Co­v­ant Ther­a­peu­tics with a $10 mil­lion up­front com­mit­ment from Boehringer In­gel­heim to turn up the heat in can­cer.

The Boston-based drug dis­cov­ery start­up will joint­ly cre­ate a new small mol­e­cule im­munother­a­py with the pri­vate Ger­man phar­ma gi­ant. The deal, made pub­lic Tues­day morn­ing, in­cludes up to $471 mil­lion in fu­ture pay­ments and tiered roy­al­ties, should the prod­uct make it to mar­ket.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.